Aizon, a San Francisco, CA-based artificial intelligence (AI) SaaS provider focusing on transforming pharmaceutical manufacturing operations, secured $20 million in Series C funding.
The round was led by NewVale Capital, with participation from existing investors Atlantic Bridge, Crosslink Capital, and Uncork Capital.
Founded in 2022, NewVale Capital is a growth equity fund specializing in investing in revenue-generating service businesses in the pharmaceutical and biotechnology sectors.
Aizon Use of Funds
The funding will enable Aizon to scale its operations, accelerate its development pipeline, and enhance its customer service capabilities. The company plans to utilize the capital to advance its strategic roadmap, with a particular focus on launching its innovative eBR (Electronic Batch Record) solution in Q3 2024.
Aizon is a developer of a data analytics and AI platform designed to improve pharma manufacturing processes. The company's platform offers acquisition, recording, visualization, and analysis of manufacturing data for the optimization of industrial processes. Aizon leverages advanced predictive analytics, artificial intelligence, and smart factory technologies to provide a powerful and accessible GMP (Good Manufacturing Practice) AI platform for pharmaceutical manufacturers. Aizon offices are located in San Francisco, California, and Barcelona, Spain.
Company: Bigfinite Inc.
Round: Series C
Funding Month: February 2024
Lead Investors: NewVale Capital
Additional Investors: Atlantic Bridge, Crosslink Capital, and Uncork Capital
Company Website: https://www.aizon.ai/
Software Category: Pharmaceutical Manufacturing Operations